Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2466
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis ; volume:21 ; number:1 ; day:11 ; month:12 ; year:2021 ; pages:1-11 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (11.12.2021), 1-11, 12.2021

Creator
Finnerty, James Patrick
Ponnuswamy, Aravind
Dutta, Prosjenjit
Abdelaziz, Ammar
Kamil, Hafiz
Contributor
SpringerLink (Online service)

DOI
10.1186/s12890-021-01783-1
URN
urn:nbn:de:101:1-2022021819370167736912
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Finnerty, James Patrick
  • Ponnuswamy, Aravind
  • Dutta, Prosjenjit
  • Abdelaziz, Ammar
  • Kamil, Hafiz
  • SpringerLink (Online service)

Other Objects (12)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht

Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)

Related objects